Apocynum venetum leaf polysaccharide and its preparation method and application
The polysaccharides AV1-N1 and AV2-N1 extracted and purified from robu saccharide leaves were solved. The problem of insufficient research on preventing and treating heart failure was demonstrated, and its significant effect in improving heart failure was demonstrated. It was a good example of heart failure. Treatment provides new scientific basis and application pathways.
Patent Information
- Application Number
- CN202410351140.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-26
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-03-26
AI Technical Summary
In the prior art, there are few researches on the prevention and treatment of cardiovascular diseases, especially its application in the prevention and treatment of heart failure has not been reported.
Two new polysaccharides were extracted and purified from the traditional Chinese medicine Robu Macao leaf, called Robu Macao leaf polysaccharides AV1-N1 and AV2-N1. Through ultrasonic extraction, enzymatic decomposition, ion exchange column and gel column chromatography, the process of determining the Its structural units and monosaccharides are composed of and their effects on improving or treating heart failure are evaluated in zebrafish models.
Robu azalea polysaccharides AV1-N1 and AV2-N1 show significant anti-heart failure activity, which can improve heart failure caused by doxorubicin, provide new drug and health products application potential, and improve scientific basis for heart failure treatment.
Smart Images

Figure CN118184809B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of preparation of active extracts of traditional Chinese medicines, and relates to apocynum venetum leaf polysaccharide and a preparation method and application thereof, and specifically relates to the extraction and purification of two new apocynum venetum leaf polysaccharides, and application thereof in preventing and treating cardiovascular diseases. Background Art
[0002] Cardiovascular disease (CVD) is a major disease that seriously endangers the health and life of the Chinese people. On November 15, 2023, the "Healthy China Action-Cardiovascular and Cerebrovascular Disease Prevention and Control Action Implementation Plan (2023-2030)" led by the National Health Commission clearly pointed out that it is necessary to "implement risk factor control to reduce the risk of morbidity and mortality" and "strengthen the forward movement of the checkpoints and innovate the prevention and treatment of cardiovascular and cerebrovascular diseases". According to the data of the "China Cardiovascular Health and Disease Report 2022", CVD ranks first in the proportion of disease deaths among urban and rural residents in my country. At present, the main causes of heart failure patients in my country are hypertension and coronary heart disease. Therefore, finding drugs with definite efficacy and few side effects to prevent and treat heart failure is crucial to improving the quality of life of patients.
[0003] Apocynum venetum L. is one of the featured Chinese medicines for the clinical treatment of hypertension. It has been included in the Chinese Pharmacopoeia since 1977. The 2020 edition of the Chinese Pharmacopoeia records that Apocynum venetum L. is sweet, bitter, and cool, and belongs to the liver meridian. It has the effects of "calming the liver and tranquilizing the mind, clearing away heat and promoting diuresis". It is mainly used in the clinical practice of traditional Chinese medicine to treat liver yang vertigo, palpitations and insomnia, edema and oliguria, which is hypertension in modern medical terms. At present, Apocynum venetum L. preparations are mainly used alone, and the indications of the 55 approved Chinese patent medicines are mostly hypertension.
[0004] The main active ingredients of Apocynum venetum leaf are small molecule flavonoid compounds. Hyperoside, the index ingredient of Apocynum venetum leaf specified in the Chinese Pharmacopoeia, is a flavonoid glycoside with a wide range of cardiovascular-related activity reports. However, the current research on the polysaccharide components of Apocynum venetum leaf is insufficient, and very few Apocynum venetum leaf polysaccharides have been reported in the literature.
[0005] In his master's thesis "Study on the Extraction and Biological Activity of Apocynum Leaf Polysaccharides", Zhou Jinhui of Qingdao University used acid (HCl), alkali (NaOH) and distilled water to extract Apocynum Leaf Polysaccharides, and studied the effects of different extraction solvents and extraction temperatures on the yield of Apocynum Leaf Polysaccharides; in addition, it was found that the antioxidant capacity and enzyme inhibition activity of Apocynum Leaf Polysaccharides extracted by alkali were the strongest. In vivo experiments on mice found that Apocynum Leaf Polysaccharides play an important role in the treatment of type II diabetes and the improvement of pancreatic β-cell function; the results of lipid profile analysis showed that Apocynum Leaf Polysaccharides are very effective in improving blood lipid levels. In his master's thesis "Isolation and Purification of Apocynum Leaf Polysaccharides, Structural Analysis and Interaction with Galectins", Wei Ningning of Northeast Normal University used dried Apocynum Leaf to extract by hot water, ethanol precipitation and Sevag method to remove proteins to obtain Apocynum Leaf Water-soluble Crude Polysaccharide ALP (5.8%). ALP was purified by column chromatography to obtain a neutral sugar fraction ALPN and two acidic sugar fractions ALPA-1 and ALPA-2. ALPA-1 and ALPA-2 were further purified into two relatively uniform polysaccharide fractions ALPA-1a and ALPA-2a. In the hemagglutination inhibition experiment, ALPA-1b and ALPA-2a showed significant activity in inhibiting hemagglutination.
[0006] Chinese patent CN109288856A provides the application of Apocynum venetum leaf polysaccharide in the preparation of hypoglycemic and / or hypolipidemic drugs. CN112516014A discloses an Apocynum venetum extract, the active ingredients of which include Apocynum venetum essential oil and Apocynum venetum polysaccharide, wherein the Apocynum venetum polysaccharide has excellent antioxidant and anti-ultraviolet radiation effects in addition to the common water-locking and moisturizing effects, and can protect the skin from external irritation, inflammation and ultraviolet pollution. CN112353733A discloses a fermentation method of Apocynum venetum fermentation product and its application in anti-inflammatory cosmetics, the fermentation method provided by the fermentation method makes the content of Apocynum venetum polysaccharide, the active ingredient, in the fermentation liquid as high as 0.56%, and the Apocynum venetum fermentation product has good in vivo anti-inflammatory activity. CN112494360A discloses an extraction method of Apocynum venetum polysaccharide extract, Apocynum venetum polysaccharide extract and application, and the Apocynum venetum polysaccharide extract has good in vivo whitening activity. CN109517087A discloses a method for preparing apocynum venetum leaf polysaccharide, comprising the steps of mixing apocynum venetum leaf with an extracting solution for extraction to obtain an extract, etc., so as to improve the yield of apocynum venetum leaf polysaccharide, but does not involve the application of apocynum venetum leaf polysaccharide.
[0007] In the existing research, most of them are aimed at optimizing the preparation process of extracts such as Apocynum venetum leaf polysaccharides, and there are few studies on its efficacy. In the current efficacy research, most of the studies are on the antioxidant, antihypertensive and antidepressant activities of Apocynum venetum leaf polysaccharides, and there are no reports on the research of Apocynum venetum leaf polysaccharides in the prevention and treatment of cardiovascular diseases. Summary of the invention
[0008] The purpose of the present invention is to solve the above-mentioned problems existing in the prior art, and proposes a polysaccharide from apocynum venetum leaf and a preparation method and application thereof. Two new polysaccharides are found from the extract of the traditional Chinese medicine apocynum venetum leaf, which are new chemical components, and experiments have found that the two polysaccharides have anti-heart failure activity.
[0009] The technical solution of the present invention is:
[0010] The invention provides a dogbane leaf polysaccharide AV1-N1. The weight average molecular weight of the polysaccharide AV1-N1 is 64.1 kDa, and the polydispersity index is 2.317. The monosaccharide composition of the polysaccharide AV1-N1 is fucose Fuc, rhamnose Ara, galactose Gal, glucose Glc, xylose Xyl, mannose Man, ribose Rib and mannuronic acid Glc-UA. The molar percentages of the fucose, rhamnose, galactose, glucose, xylose, mannose, ribose and mannuronic acid are 0.13%, 40.23%, 50.00%, 2.05%, 1.58%, 1.41%, 0.80% and 3.80% respectively.
[0011] Furthermore, the polysaccharide AV1-N1 has the following structural units:
[0012]
[0013] The invention also provides a dogbane leaf polysaccharide AV2-N1, the weight average molecular weight of the polysaccharide AV2-N1 is 58.8 kDa, and the polydispersity index is 1.753; the monosaccharide composition of the polysaccharide AV2-N1 is fucose Fuc, rhamnose Ara, galactose Gal, glucose Glc, xylose Xyl, mannose Man, galacturonic acid Gal-UA and mannuronic acid Glc-UA, and the molar percentages of the fucose, rhamnose, galactose, glucose, xylose, mannose, galacturonic acid and mannuronic acid are 0.95%, 50.04%, 37.31%, 0.95%, 1.09%, 0.68%, 3.56% and 5.42% respectively.
[0014] Furthermore, the polysaccharide AV2-N1 has the following structural units:
[0015]
[0016] Furthermore, the preparation method of the above-mentioned Apocynum venetum leaf polysaccharide AV1-N1 and / or Apocynum venetum leaf polysaccharide AV2-N1 comprises the following steps:
[0017] (1) taking dried Apocynum venetum leaves, crushing and sieving, adding anhydrous ethanol to extract by ultrasonic at room temperature, combining the extracts, collecting the precipitate by centrifugation, adding an appropriate amount of pure water to the precipitate, ultrasonic extraction at 60° C., combining the extracts again, centrifuging, collecting the supernatant extract, concentrating the extract to 1 / 10 of the original volume at 45° C., adding 4 times the volume of anhydrous ethanol to precipitate overnight at 4° C., and collecting the solid precipitate by centrifugation to obtain a crude polysaccharide extract;
[0018] (2) adding an appropriate amount of pure water and papain to the crude polysaccharide extract, and performing enzymolysis overnight; then adding an appropriate amount of chloroform and n-butanol, stirring and mixing thoroughly, and collecting the upper aqueous phase; then adding an appropriate amount of petroleum ether, stirring and mixing thoroughly, and collecting the lower aqueous phase; finally, adding an appropriate amount of AB-8 macroporous adsorption resin to the aqueous phase, stirring thoroughly, and standing overnight; collecting the filtrate, dialyzing, and freeze-drying to obtain apocynum venetum leaf crude polysaccharide;
[0019] (3) taking an appropriate amount of crude polysaccharide and dissolving it in pure water to prepare a polysaccharide mother solution with a concentration of 10 mg / mL, centrifuging to obtain the supernatant, eluting with an ion exchange column, collecting the eluate, concentrating under reduced pressure, dialyzing, and freeze-drying to obtain several crude polysaccharide components;
[0020] (4) A crude polysaccharide purified by ion column was added with pure water to prepare a polysaccharide mother liquor with a concentration of 15 mg / mL, and the supernatant was obtained by centrifugation. The supernatant was eluted using a gel column chromatography column, and the eluate was collected and concentrated under reduced pressure, dialyzed, and freeze-dried to obtain polysaccharide AV1-N1. The same operation was used to perform gel column chromatography on another crude polysaccharide component purified by ion column to obtain polysaccharide AV2-N1.
[0021] Furthermore, in step (3), a DEAE seplife FF anion exchange column with a size of 26 mm×400 mm is used, and pure water, 0.1 mol / L, 0.2 mol / L and 0.3 mol / L sodium chloride solution are used in sequence for gradient elution at a flow rate of 4 mL / min; in step (4), a Sephacryl S-400HR gel column chromatography column with a size of 26 mm×1000 mm is used, and pure water is used for elution at 1.5 times the column volume at a flow rate of 1 mL / min.
[0022] The present invention also provides the use of the above-mentioned Apocynum venetum leaf polysaccharide AV1-N1 and / or Apocynum venetum leaf polysaccharide AV2-N1 in the preparation of a medicine for improving or treating heart failure.
[0023] The present invention also provides the use of the above-mentioned Apocynum venetum leaf polysaccharide AV1-N1 and / or Apocynum venetum leaf polysaccharide AV2-N1 in the preparation of food and health products for improving heart failure.
[0024] The present invention further provides a medicine for improving or treating heart failure, wherein the medicine contains the above-mentioned Apocynum venetum leaf polysaccharide AV1-N1 and / or Apocynum venetum leaf polysaccharide AV2-N1.
[0025] The zebrafish model has unique advantages in screening cardioprotective active ingredients. The zebrafish heart is highly similar to the human heart in structure, function, signaling pathways and ion channels, and its blood lipid composition and metabolism are basically the same as those of humans. In addition, the embryos and their larvae are almost transparent, and the cardiovascular system is visible, so the heartbeat, angiogenesis and vascular lesions can be observed in vivo. Based on this, the present invention prepares two types of Apocynum venetum leaf polysaccharides, and evaluates the efficacy of Apocynum venetum leaf polysaccharides in improving heart failure caused by doxorubicin, providing a scientific basis for its clinical application.
[0026] Beneficial effects of the present invention:
[0027] The invention further purifies two new polysaccharides AV1-N1 and AV2-N1 from the extract of the traditional Chinese medicine Apocynum venetum leaf, and obtains the molecular weight and monosaccharide composition of the two polysaccharides through purity and molecular weight determination and monosaccharide composition test, wherein the number average molecular weights of polysaccharides AV1-N1 and AV2-N1 are 27.7 and 33.6 kDa, respectively, the peak molecular weights are 29.9 and 55.3 kDa, respectively, the weight average molecular weights are 64.1 and 58.8 kDa, respectively, and the z average molecular weights are 590.8 and 164.1 kDa, respectively. kDa, and the polydispersity indexes are 2.317 and 1.753 respectively; the monosaccharide composition of polysaccharide AV1-N1 is fucose, rhamnose, galactose, glucose, xylose, mannose, ribose, and mannuronic acid; the monosaccharide composition of AV2-N1 is fucose, rhamnose, galactose, glucose, xylose, mannose, galacturonic acid and mannuronic acid; the type and connection order of the glycosidic bonds of the two polysaccharides, as well as the structural information such as the connection site between the main chain and the branch chain are obtained by monosaccharide methylation test and polysaccharide nuclear magnetic resonance detection, and the structural unit of the polysaccharide is obtained. Based on the zebrafish model, the present invention experiments on the efficacy of the above two polysaccharides in improving or treating heart failure caused by doxorubicin, and finds that the two polysaccharides have anti-heart failure activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 are elution curves; wherein, (A) is the elution curve of the ion column, (B) is the elution curve of the AV1-N1 gel column, and (C) is the elution curve of the AV2-N1 gel column;
[0029] Figure 2 The diagrams are molecular configuration analysis diagrams and absolute molecular weight analysis diagrams; wherein, (A) is the molecular configuration analysis diagram of AV1-N1; (B) is the absolute molecular weight analysis diagram of AV1-N1; (C) is the molecular configuration analysis diagram of AV2-N1; (D) is the absolute molecular weight analysis diagram of AV2-N1;
[0030] Figure 3 are ion chromatograms, wherein (A) is the standard sample ion chromatogram, (B) is the AV1-N1 sample ion chromatogram, and (C) is the AV2-N1 sample ion chromatogram;
[0031] Figure 4 methylation GC / MS total ion current diagram, wherein (A) is the methylation GC / MS total ion current diagram of AV1-N1 sample, and (B) is the methylation GC / MS total ion current diagram of AV2-N1;
[0032] Figure 5 NMR spectra of AV1-N1 and AV2-N1;
[0033] Figure 6 The results of the anti-heart failure activity of polysaccharides AV1-N1 and AV2-N1; wherein, (A) is a typical bright field side view and cardiac fluorescence image of each group of zebrafish, (B) is a statistical graph of pericardial area, (C) is a statistical graph of heart rate, (D) is a statistical graph of short-axis shortening rate, (E) is a statistical graph of ejection fraction, (F) is a statistical graph of stroke volume, and (G) is a statistical graph of stroke volume. DETAILED DESCRIPTION
[0034] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0035] In order to further understand the present invention, the present invention will be further described in conjunction with the accompanying drawings and embodiments.
[0036] Example 1 Extraction and purification of polysaccharides from Apocynum venetum leaves
[0037] 1. Extraction of polysaccharides
[0038] Take 500g of dried Apocynum venetum leaves, crush them, pass through a 60-mesh sieve, transfer them to a round-bottom flask, add an appropriate amount of anhydrous ethanol, and perform ultrasonic extraction at room temperature for 3 times, each time for 30 minutes. After the extracts are combined, centrifuge at 6000×g for 10 minutes, collect the precipitate, add an appropriate amount of pure water, perform ultrasonic extraction at 60°C for 3 times, each time for 60 minutes, combine the extracts, centrifuge at 6000×g for 10 minutes, and collect the supernatant extract. Concentrate the extract at 45°C to 1 / 10 of the original volume, add 4 times the volume of anhydrous ethanol and precipitate overnight at 4°C, then centrifuge at 8000×g for 10 minutes, collect the solid precipitate, and obtain a crude polysaccharide extract.
[0039] Add appropriate amount of pure water and papain to the crude extract for overnight enzymolysis; then, add appropriate amount of chloroform and n-butanol, stir and mix thoroughly, collect the upper aqueous phase; then add appropriate amount of petroleum ether, stir and mix thoroughly, collect the lower aqueous phase. Finally, add appropriate amount of AB-8 macroporous adsorption resin to the aqueous phase, mix thoroughly, and let stand overnight. Collect the filtrate, and finally dialyze it with a 3000Da dialysis bag for 48 hours, and then freeze-dry the remaining liquid to obtain 6.92g of crude polysaccharide from Apocynum venetum leaves. The polysaccharide content was 84.5% measured by sulfuric acid phenol method, and it was set aside.
[0040] 2. Purification of polysaccharides
[0041] Take an appropriate amount of crude polysaccharide and dissolve it in pure water to prepare a polysaccharide mother solution with a concentration of 10 mg / mL; centrifuge at 10000×g for 10 minutes, take the supernatant and elute it on a DEAE seplife FF anion exchange column (26mm×400mm); use pure water, 0.1mol / L, 0.2mol / L and 0.3mol / L sodium chloride solution in turn for gradient elution, flow rate 4mL / min, collect 1 tube for every 15mL, and number them in sequence. Use sulfuric acid-phenol method to determine the polysaccharide content of each tube of eluate, and draw the following figure: Figure 1 (A) Ion purification elution curve shown. According to the polysaccharide content determination results, the eluates from each collection tube corresponding to the same elution peak were combined, concentrated to 1 / 5 of the original volume at 45°C under reduced pressure, and then dialyzed for 48 hours using a 3000Da dialysis bag. The remaining liquid was freeze-dried to obtain 4 crude polysaccharide components, corresponding to Figure 1 (A) The four peaks are numbered 1, 2, 3, and 4.
[0042] Take the crude polysaccharide component corresponding to peak 3 after ion column purification, add pure water to make a polysaccharide mother solution with a concentration of 15 mg / mL; centrifuge at 10000×g for 10 minutes, take the supernatant and elute it on a Sephacryl S-400HR gel column chromatography column (26mm×1000mm), use pure water to elute 1.5 times the column volume, flow rate 1mL / min, collect 1 tube for every 12mL, and number them in sequence. The polysaccharide content of each tube of eluate was determined by sulfuric acid-phenol method, and the following was plotted: Figure 1 (B) and Figure 1 (C) shows the gel purification elution curve. According to the polysaccharide content determination results, the eluates from each collection tube corresponding to the main peak were combined, concentrated to 1 / 5 of the original volume at 45°C under reduced pressure, and then dialyzed for 48 hours using a 3000Da dialysis bag. The remaining liquid was freeze-dried to obtain a uniform polysaccharide ( Figure 1(B)), named AV1-N1, weight 235.9 mg. The crude polysaccharide component corresponding to peak 4 after ion column purification was subjected to Sephacryl S-400HR gel column chromatography to obtain a uniform polysaccharide ( Figure 1 (C)), named AV2-N1, weight 192.3 mg.
[0043] Example 2 Purity and Molecular Weight Determination of Polysaccharides
[0044] The purity and molecular weight of polysaccharides were determined by gel chromatography-differential refractive index-multi-angle laser light scattering system. The liquid phase system was U3000 (Thermo), equipped with Optilab T-rEX differential refractive index detector (Wyatt technology) and DAWN HELEOSⅡ laser light scattering detector (Wyatt technology). The gel exclusion chromatography columns included Ohpak SB-805HQ (300×8mm), Ohpak SB-804HQ (300×8mm), and Ohpak SB-803HQ (300×8mm) connected in series.
[0045] First, the sample was dissolved in 0.1mol / L NaNO3 aqueous solution (containing 0.02% NaN3, w / w) to a final concentration of 1mg / mL, filtered through a 0.45μm filter membrane and tested on the machine. The injection volume was 100μL, the column temperature was 45℃, the mobile phase A was 0.1mol / L NaNO3 aqueous solution (containing 0.02% NaN3, w / w), the flow rate was 0.4mL / min, and the elution gradient was isocratic for 100min.
[0046] The absolute molecular weight analysis graph is drawn with the detected retention time as the horizontal axis and the molar mass as the vertical axis; the molecular configuration graph is drawn with the molar mass as the horizontal axis and the root mean square radius as the vertical axis. Figure 2 The absolute molecular weight analysis diagram and molecular configuration analysis diagram of the sample are shown, among which, Figure 2 (A) is the molecular configuration analysis diagram of polysaccharide AV1-N1. Figure 2 (B) is the absolute molecular weight analysis chart of polysaccharide AV1-N1. Figure 2 (C) is the molecular configuration analysis diagram of polysaccharide AV2-N1. Figure 2 (D) is the absolute molecular weight analysis chart of polysaccharide AV2-N1. It is calculated from the chart that the number average molecular weight (Mn) of polysaccharides AV1-N1 and AV2-N1 are 27.7 and 33.6 kDa, respectively; the peak molecular weight (Mp) are 29.9 and 55.3 kDa, respectively; the weight average molecular weight (Mw) are 64.1 and 58.8 kDa, respectively; the z-average molecular weight (Mz) are 590.8 and 164.1 kDa, respectively; and the polydispersity index (Mw / Mn) are 2.317 and 1.753, respectively.
[0047] Example 3 Monosaccharide composition test
[0048] The chromatographic system used was the Thermo ICS5000 ion chromatography system, and the monosaccharide components were analyzed and detected using an electrochemical detector. TM CarboPac TM PA20 (150*3.0mm, 10μm) liquid chromatography column; injection volume was 5μl. Mobile phase A was H2O, mobile phase B was 0.1mol / LNaOH, and mobile phase C was 0.1mol / LNaOH (containing 0.2M NaAc), flow rate 0.5 mL / min; column temperature 30°C; elution gradient: 0 min, phase A / phase B / phase C (95:5:0, V / V / V); 26 min, phase A / phase B / phase C (85:5:10, V / V / V); 42 min, phase A / phase B / phase C (85:5:10, V / V / V); 42.1 min, phase A / phase B / phase C (60:0:40, V / V / V); 52 min, phase A / phase B / phase C (60:40:0, V / V / V); 52.1 min, phase A / phase B / phase C (95:5:0, V / V / V); 60 min, phase A / phase B / phase C (95:5:0, V / V / V).
[0049] Weigh an appropriate amount of AV1-N1 and AV2-N1 polysaccharide samples, add 1mL of 2mol / LTFA acid solution, heat at 121℃ for 2 hours, pass nitrogen, blow dry; add 99.99% methanol to wash, blow dry again, and repeat the methanol washing 2-3 times. Add sterile water to dissolve and transfer to a chromatographic bottle for testing. Then accurately weigh the required monosaccharide standards as shown in Table 1, add water to make a 10mg / mL standard solution mother solution single standard, then take an appropriate amount of standard mother solution single standard and mix to make a standard mixed standard with a maximum index concentration of 50μg / mL, and then dilute to 25μg / mL, 20μg / mL, 10μg / mL, 5μg / mL, 1μg / mL and 0.5μg / mL series concentrations.
[0050] The external standard method was used for quantification. The standard curve was established by preparing standard samples of different concentrations. The horizontal axis was the retention time and the vertical axis was the response value. Figure 3 The standard sample ion chromatogram and sample ion chromatogram are shown. Figure 3 (A) is the ion chromatogram of the standard sample. Figure 3 (B) is the ion chromatogram of polysaccharide AV1-N1. Figure 3 (C) is the ion chromatogram of polysaccharide AV2-N1.
[0051] The monosaccharide standard curve and the measured values of AV1-N1 and AV2-N1 are shown in Table 1:
[0052] Table 1 Summary of monosaccharide labeling information and molecular weights of AV1-N1 and AV2-N1 polysaccharide samples
[0053]
[0054] Example 4 Monosaccharide methylation test
[0055] The analytical instrument used in this embodiment is an Agilent 7890A-5977B gas chromatograph, and the autosampler model is G4567A. The chromatographic system uses an Agilent gas chromatograph system Agilent 7890A, and the chromatographic column is BPX70 (30m×0.25mm×0.25μm, SGE). The injection volume is 1μl, the split ratio is 10:1, and the carrier gas is high-purity helium; the initial temperature of the column oven is 140°C for 2.0 minutes, and the temperature is raised to 230°C at 3°C / min and maintained for 3 minutes.
[0056] The mass spectrometry system used was the Agilent 5977B quadrupole mass spectrometry detection system from Aiglent, USA, equipped with an electron impact ion source (EI) and a MassHunter workstation. Using the electron impact ion source (EI), the analytes were detected in full scan (SCAN) mode, with a mass scan range (m / z): 50-350.
[0057] Take 2-3 mg of AV1-N1 and AV2-N1 polysaccharide samples, add 500 μl DMSO to dissolve. Add 1 mg NaOH, incubate for 30 min, add 50 μl iodomethane solution to react for 1 h, add 1 mL water and 2 mL dichloromethane, vortex to mix, centrifuge, and discard the aqueous phase. Repeat the water wash 3 times, aspirate the lower dichloromethane phase and blow dry with nitrogen. Add 100 μl 2M TFA, react at 121℃ for 90 min; evaporate to dryness at 30℃. Add 50 μl 2M ammonia water, 50 μl 1M NaBD4, mix well, and react at room temperature for 2.5 h. Add 20 μl acetic acid to terminate the reaction, blow dry with nitrogen, wash twice with 250 μl methanol, blow dry with nitrogen. Add 250 μl acetic anhydride, vortex to mix, and react at 100℃ for 2.5 h. Add 1 mL of water and let stand for 10 min; add 500 μl of dichloromethane, vortex mix, centrifuge, discard the water phase, repeat water washing 3 times; take the lower dichloromethane phase, and detect it on GC-MS to obtain the following Figure 4 Methylation GC / MS total ion chromatograms of AV1-N1 and AV2-N1 are shown.
[0058] The bonding structure analysis results of AV1-N1 and AV2-N1 are shown in Table 2:
[0059] Table 2 Results of bonding structure analysis of polysaccharide samples
[0060]
[0061] Note: *Relative molar amount = peak area / molecular weight; *Relative molar ratio (%) = relative molar amount / sum of relative molar amounts of each component.
[0062] Example 5 Nuclear magnetic resonance detection of polysaccharides
[0063] The target was quantitatively analyzed using a Bruker 600MHz NMR spectrometer with a scanning temperature of 25°C. Liquid probe QXI 1H / 31P / 13C / 15N 5mm quadruple resonance reverse detection probe (Z-gradient, ATMAcc), technical parameters: signal-to-noise ratio (1H): 888; resolution (Hz): 0.32 (rotating) BBFO 1H-19F, 31P-15N, 1H decoupling / observe multi-nuclear forward detection probe (Z-gradient, ATM). Technical parameters: signal-to-noise ratio (1H): 798; resolution (Hz): 0.26 (rotating); signal-to-noise ratio (13C): 328; resolution (Hz): 0.1.
[0064] Take an appropriate amount of AV1-N1 polysaccharide sample and fully dissolve it in D2O to prepare a polysaccharide solution with a concentration greater than or equal to 40 mg / mL. Transfer the dissolved solution to an NMR tube and add 0.5 mL. Place the NMR tube in an NMR spectrometer and scan it in one dimension. 1 H spectrum, 13 C spectra, HSQC and HMBC spectra, such as Figure 5 shown.
[0065] Combining the one-dimensional NMR and two-dimensional NMR spectra, the sugar residue signals of the AV1-N1 polysaccharide sample were assigned as shown in the following table:
[0066] Table 3 Sugar residues of AV1-N1 1 H and 13 Chemical shift of C
[0067]
[0068] According to the sugar residues in AV1-N1 sample 13 C and 1The chemical shift of H was combined with the HMBC spectrum to analyze the connection mode of the structural fragments in the polysaccharide: there is a cross peak of δ5.17 / 80.24ppm between sugar residue A-H1 and residue B-C3, and a cross peak of δ109.28 / 3.68ppm between sugar residue A-C1 and residue B-H3. There is a cross peak of δ4.42 / 69.49ppm between sugar residue B-H1 and residue B-C6, and a cross peak of δ4.42 / 69.41ppm between sugar residue B-C1 and residue E-H5. There is a cross peak of δ103.41 / 3.82ppm (the cross peak signal is relatively weak). There is a cross peak of δ4.46 / 69.49ppm between sugar residue D-H1 and residue B-C6. There is a cross peak of δ5.02 / 81.98ppm between sugar residue E-H1 and residue D-C3. Combined with the NOESY spectrum, the connection order of each residue in the polysaccharide was further judged and verified. The sugar residue A-H1 and residue B-H3 had a cross peak of δ5.17 / 3.68ppm. The sugar residue B-H1 and residue B-H6 had a cross peak of δ4.42 / 3.87ppm, and a cross peak of δ4.42 / 3.86ppm with residue C-H6. The sugar residue C-H1 had a cross peak of δ4.62 / 3.98ppm with residue B-H6, and a cross peak of δ4.62 / 3.86ppm with residue C-H6. The sugar residue D-H1 had a cross peak of δ4.46 / 3.87ppm with residue B-H6. Therefore, based on the analysis of one-dimensional and two-dimensional NMR information, it is inferred that the main chain of the polysaccharide is mainly composed of →6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→ and a small amount of →5)-α-L-Araf-(1→, and the main branch chain is composed of α-L-Araf-(1→ connected to the O-3 position of the sugar residue →3,6)-β-D-Galp-(1→. Combined with the bonding structure (methylation) information, the structure of the polysaccharide chain is inferred to be:
[0069]
[0070] Combining the one-dimensional NMR and two-dimensional NMR spectra, the sugar residue signals of the AV2-N1 polysaccharide sample were assigned as shown in the following table:
[0071] Table 4 Sugar residues of AV2-N1 1 H and 13 Chemical shift of C
[0072]
[0073] According to the sugar residues in AV2-N1 sample 13 C and 1H chemical shift, combined with HMBC spectrum analysis of the connection mode of the structural fragments in the polysaccharide: sugar residue A-H1 and residue B-C3 have a cross peak of δ5.17 / 80.1ppm. Sugar residue B-H1 and residue B-C6 have a cross peak of δ4.44 / 69.18ppm. Sugar residue C-H1 and residue B-C6 have a cross peak of δ4.67 / 69.18ppm, and a cross peak of δ4.67 / 79.12ppm with residue C-C4; sugar residue C-C1 and residue C-C4 have a cross peak of δ100.79 / 3.51ppm. Combined with NOESY spectrum, the connection order of each residue in the polysaccharide was further judged and verified. Sugar residue A-H1 and residue B-H3 have a cross peak of δ5.17 / 3.66ppm. Sugar residue B-H1 and residue B-H6 have a cross peak of δ4.44 / 3.85ppm. There is a cross peak δ4.67 / 3.51ppm between the sugar residue C-H1 and the residue C-H4. Therefore, based on the analysis of the one-dimensional and two-dimensional nuclear magnetic resonance information, it is inferred that the polysaccharide is mainly composed of →3,6)-β-D-Galp-(1→ O-6 and →4)-β-D-Galp-(1→ interconnected, and the branch chain is mainly composed of α-L-Araf-(1→ connected to the sugar residue →3,6)-β-D-Galp-(1→ O-3 position. Combined with the bonding structure (methylation) information, the structure of the polysaccharide chain is inferred to be:
[0074]
[0075] Example 6 Polysaccharide activity in improving or treating adriamycin-induced heart failure
[0076] 3dpf wild-type AB healthy zebrafish were selected and placed in a 24-well plate, with 10 in each well. A blank group for control and six polysaccharide administration groups of 10μg / mL, 50μg / mL, 100μg / mL, 200μg / mL, 400μg / mL, and 800μg / mL were set up. After incubation for 24 hours, photos were taken and observed, and the deformity rate and mortality rate of zebrafish in each group were counted. The subsequent activity evaluation experiment administration concentration was determined based on the safe concentration. The results showed that compared with the blank group, 10-800μg / mLAV1-N1 and AV2-N1 did not cause zebrafish deformity or death. Concentrations below 800μg / mL can be selected as activity evaluation administration concentrations.
[0077] Transgenic zebrafish Tg (cmLc2: EGFP) with cardiac fluorescence markers were selected, and 2dpf healthy zebrafish were transferred to 24-well plates, with 10 in each well, and divided into blank group, model group (60μM doxorubicin DOX), positive drug group (200μM dexrazoxane DXZ), and DOX and polysaccharide combined administration group (the final concentrations of AV1-N1 and AV2-N1 were 50μg / mL, 100μg / mL, and 200μg / mL). After incubation in the dark for 24 hours, photos were taken under the bright field of a microscope to observe the heart rate and pericardial area of each group of zebrafish, and statistical analysis was performed. The heartbeat videos of each group of zebrafish were observed and recorded under an inverted fluorescence microscope, and the end-diastolic and end-systolic images were extracted to calculate the ventricular short axis shortening rate, stroke volume, and ejection fraction.
[0078] like Figure 6 As shown in (A), the pericardial edema area of zebrafish in the doxorubicin treatment group (DOX) was significantly increased, the heart rate was significantly decreased, and the ventricular short axis shortening rate, stroke volume and ejection fraction were significantly reduced, indicating that the model was successfully established.
[0079] like Figure 6 As shown in (B), in the group of DOX and polysaccharide co-administration (Sugars), 50μg / mL, 100μg / mL, and 200μg / mL of AV1-N1 and AV2-N1 could significantly improve doxorubicin-induced pericardial edema in zebrafish in a dose-dependent manner; 200μg / mL of AV2-N1 was even better than the positive drug dexrazoxane (DXZ).
[0080] like Figure 6 As shown in (C), 50 μg / mL, 100 μg / mL, and 200 μg / mL of AV1-N1 and AV2-N1 can significantly increase heart rate. The improvement of AV2-N1 is dose-dependent. 100 μg / mL and 200 μg / mL of AV2-N1 are even better than the positive drug dexrazoxane.
[0081] like Figure 6 As shown in (D), the positive drugs dexrazoxane, AV1-N1 and AV2-N1 had no significant effect on improving the short-axis shortening rate.
[0082] like Figure 6 As shown in (E), 50 μg / mL, 100 μg / mL, and 200 μg / mL of AV1-N1 and AV2-N1 can significantly improve the reduced ejection fraction caused by doxorubicin, and 100 μg / mL of AV2-N1 is even better than the positive drug dexrazoxane.
[0083] like Figure 6As shown in (F), 50 μg / mL, 100 μg / mL, and 200 μg / mL of AV1-N1 and AV2-N1 can improve the decrease in stroke volume caused by doxorubicin, but the effects are weaker than those of the positive drug dexrazoxane.
[0084] like Figure 6 As shown in (G), 50 μg / mL, 100 μg / mL, and 200 μg / mL of AV1-N1 and AV2-N1 can improve the decrease in cardiac output caused by doxorubicin. Compared with the model group, there are significant differences at the concentrations of 100 μg / mL and 200 μg / mL, but the effects are weaker than those of the positive drug dexrazoxane.
[0085] Based on the above information, it is shown that the polysaccharides AV1-N1 and AV2-N1 from the leaves of Apocynum venetum can significantly improve doxorubicin-induced heart failure, and have significant therapeutic effects on doxorubicin-induced heart failure, and have potential clinical application value.
[0086] The above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art can still modify the technical solutions described in the above embodiments, or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, modification, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A polysaccharide from Apocynum venetum leaf AV1-N1, characterized in that: The weight average molecular weight of the polysaccharide AV1-N1 is 64.1 kDa, and the polydispersity index is 2.317; its monosaccharide composition is fucose Fuc, rhamnose Ara, galactose Gal, glucose Glc, xylose Xyl, mannose Man, ribose Rib and mannuronic acid Glc-UA, and the molar percentages of fucose, rhamnose, galactose, glucose, xylose, mannose, ribose and mannuronic acid are 0.13%, 40.23%, 50.00%, 2.05%, 1.58%, 1.41%, 0.80% and 3.80% respectively.
2. The Apocynum venetum leaf polysaccharide AV1-N1 according to claim 1, characterized in that: The polysaccharide AV1-N1 has the following structural units:
3. A polysaccharide from Apocynum venetum leaf AV2-N1, characterized in that: The weight-average molecular weight of the polysaccharide AV2-N1 is 58.8 kDa, and the polydispersity index is 1.753; its monosaccharide composition is fucose Fuc, rhamnose Ara, galactose Gal, glucose Glc, xylose Xyl, mannose Man, galacturonic acid Gal-UA and mannuronic acid Glc-UA, and the molar percentages of fucose, rhamnose, galactose, glucose, xylose, mannose, galacturonic acid and mannuronic acid are 0.95%, 50.04%, 37.31%, 0.95%, 1.09%, 0.68%, 3.56% and 5.42% respectively.
4. The Apocynum venetum leaf polysaccharide AV2-N1 according to claim 3, characterized in that The polysaccharide AV2-N1 has the following structural units:
5. The method for preparing the Apocynum venetum leaf polysaccharide AV1-N1 according to claim 1 and / or the Apocynum venetum leaf polysaccharide AV2-N1 according to claim 3, characterized in that: The following steps are involved: (1) taking dried Apocynum venetum leaves, crushing and sieving, adding anhydrous ethanol to extract by ultrasonic method at room temperature, combining the extracts, collecting the precipitate by centrifugation, adding pure water to the precipitate, ultrasonic extraction at 60° C., combining the extracts again, centrifuging, collecting the supernatant extract, concentrating the extract to 1 / 10 of the original volume at 45° C. under reduced pressure, adding 4 times the volume of anhydrous ethanol to precipitate overnight at 4° C., and collecting the solid precipitate by centrifugation to obtain a crude polysaccharide extract; (2) adding purified water and papain to the crude polysaccharide extract and performing enzymatic hydrolysis overnight; then adding chloroform and n-butanol, stirring and mixing thoroughly, and collecting the upper aqueous phase; Then petroleum ether is added, the mixture is stirred and mixed thoroughly, and the lower aqueous phase is collected; finally, AB-8 macroporous adsorption resin is added to the aqueous phase, the mixture is stirred and mixed thoroughly, and the mixture is allowed to stand overnight; the filtrate is collected, dialyzed, and freeze-dried to obtain apocynum venetum leaf crude polysaccharide; (3) dissolving the crude polysaccharide in pure water to prepare a polysaccharide mother solution with a concentration of 10 mg / mL, centrifuging to obtain the supernatant, eluting with an ion exchange column, collecting the eluate, concentrating under reduced pressure, dialyzing, and freeze-drying to obtain four crude polysaccharide fractions; (4) A crude polysaccharide purified by ion column was added with pure water to prepare a polysaccharide mother liquor with a concentration of 15 mg / mL, and the supernatant was obtained by centrifugation. The supernatant was eluted using a gel column chromatography column, and the eluate was collected and concentrated under reduced pressure, dialyzed, and freeze-dried to obtain polysaccharide AV1-N1. The same operation was used to perform gel column chromatography on another crude polysaccharide component purified by ion column to obtain polysaccharide AV2-N1.
6. The preparation method according to claim 5, characterized in that: In the step (3), a DEAE seplife FF anion exchange column with a size of 26 mm×400 mm is used, and pure water, 0.1 mol / L, 0.2 mol / L and 0.3 mol / L sodium chloride solution are used in sequence for gradient elution at a flow rate of 4 mL / min. In the step (4), a Sephacryl S-400HR gel column chromatography column with a size of 26 mm×1000 mm is used, and pure water is used for elution at 1.5 times the column volume at a flow rate of 1 mL / min.
7. Use of the Apocynum venetum leaf polysaccharide AV1-N1 according to any one of claims 1 to 2 and / or the Apocynum venetum leaf polysaccharide AV2-N1 according to any one of claims 3 to 4 in the preparation of a medicament for improving or treating heart failure.
8. Use of the Apocynum venetum leaf polysaccharide AV1-N1 according to any one of claims 1 to 2 and / or the Apocynum venetum leaf polysaccharide AV2-N1 according to any one of claims 3 to 4 in the preparation of foods and health products for improving heart failure.
9. A medicine for treating heart failure, characterized in that: The medicine contains the Apocynum venetum leaf polysaccharide AV1-N1 described in any one of claims 1-2 and / or the Apocynum venetum leaf polysaccharide AV2-N1 described in any one of claims 3-4.
